The DOI matches its Crossref record; 314 of the 314 references it cites were found in a registry or an index.
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Open accessAbstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the expression of genes responsible for energy metabolism, cellular development, and differentiation. Their crucial biological roles dictate the significance of PPAR-targeting synthetic ligands in medical research and drug discovery. Clinical implications of PPAR agonists span across a wide range of health conditions, including metabolic diseases, chronic inflammatory diseases, infections, autoimmune diseases, neurological and psychiatric disorders, and malignancies. In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and challenges. Findings from clinical trials revealed that different agonists of the same PPAR subtype could present different safety profiles and clinical outcomes in a disease-dependent manner. Pemafibrate, due to its high selectivity, is likely to replace other PPARα agonists for dyslipidemia and cardiovascular diseases. PPARγ agonist pioglitazone showed tremendous promises in many non-metabolic disorders like chronic kidney disease, depression, inflammation, and autoimmune diseases. The clinical niche of PPARβ/δ agonists is less well-explored. Interestingly, dual- or pan-PPAR agonists, namely chiglitazar, saroglitazar, elafibranor, and lanifibranor, are gaining momentum with their optimistic outcomes in many diseases including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and primary biliary cholangitis. Notably, the preclinical and clinical development for PPAR antagonists remains unacceptably deficient. We anticipate the future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics. This will open new possibilities for PPAR ligands in medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–314 of 314
Smith, R. C., Jin, H., Li, C., Bark, N. M., Shekhar, A., Dwivedi, S., Mortiere, C., Lohr, J. B., Hu, Q., & Davis, J. M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.10.023 · Cited by 54
Jin, S., Park, C. ‐., Cho, Y. M., Ku, B. J., Ahn, C. W., Cha, B. ‐., Min, K. W., Sung, Y., Baik, S. H., Lee, K. W., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12435 · Cited by 52
Ratner, R. E., Parikh, S. J., & Tou, C. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.042 · Cited by 52
Dixon, A. E., Subramanian, M., DeSarno, M., Black, K. E., Lane, L., & Holguín, F. (2015) · Respiratory Research · doi:10.1186/s12931-015-0303-6 · Cited by 50
on behalf of the FIELD Study Investigators, d’Emden, M. C., Jenkins, A. J., Li, L., Zannino, D., Mann, K. P., Best, J. D., Stuckey, B. G. A., Park, K., Saltevo, J., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3344-3 · Cited by 49
Shahin, D., Toraby, E. E., Abdel-Malek, H., Boshra, V., Elsamanoudy, A. Z., & Shaheen, D. (2011) · Clinical Medicine Insights Arthritis and Musculoskeletal Disorders · doi:10.4137/cmamd.s5951 · Cited by 49
Richards, D. B., Bareille, P. J., Lindo, E. L., Quinn, D., & Farrow, S. N. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.11.006 · Cited by 49
Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis
Malhotra, A., Shafiq, N., Rajagopalan, S., Dogra, S., & Malhotra, S. (2012) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2011-100388 · Cited by 49
Bays, H. E., McElhattan, J., & Bryzinski, B. S. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.039 · Cited by 49
Wang, W., Zhou, X., Kwong, J. S., Li, L., Li, Y., & Sun, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-01965-0 · Cited by 48
A pilot dose finding study of pioglitazone in autistic children
Capano, L., Dupuis, A., Brian, J. A., Mankad, D., Genore, L., Adams, R. H., Smile, S., Lui, T., Odrobina, D., Foster, J. A., et al. (2018) · Molecular Autism · doi:10.1186/s13229-018-0241-5 · Cited by 48
Du, Q., Yang, S., Wang, Y.-J., Wu, B., Zhao, Y.-Y., & Fan, B. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0044-6 · Cited by 47
The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver Disease
Akyüz, F., Demır, K., Özdil, S., Aksoy, N., Poturoğlu, Ş., İbrişim, D., Kaymakoğlu, S., Besisik, F. S., Boztaş, G., Çakaloğlu, Y., et al. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9145-x · Cited by 47
Hildreth, K. L., Pelt, R. E. V., Moreau, K. L., Grigsby, J., Hoth, K. F., Pelak, V. S., Anderson, C. A., Parnes, B. L., Kittelson, J. M., Wolfe, P., et al. (2015) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000371509 · Cited by 47
Ormseth, M. J., Oeser, A. M., Cunningham, A., Bian, A., Shintani, A., Solus, J. F., Tanner, S. B., & Stein, C. M. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4290 · Cited by 47
Puligheddu, M., Melis, M., Pillolla, G., Milioli, G., Parrino, L., Terzano, G., Aroni, S., Sagheddu, C., Marrosu, F., Pistis, M., et al. (2017) · Epilepsia · doi:10.1111/epi.13863 · Cited by 46
van de Weijer, T., Havekes, B., Bilet, L., Joris Hoeks, J., Sparks, L. M., Bosma, M., Paglialunga, S., Jörgensen, J. A., Janssen, M. C. H., Schaart, G., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.300944 · Cited by 45
A Randomized, Placebo‐Controlled Trial of Rosiglitazone for HIV‐Related Lipoatrophy
Cavalcanti, R. B., Raboud, J., Shen, S., Kain, K. C., Cheung, A. M., & Walmsley, S. L. (2007) · The Journal of Infectious Diseases · doi:10.1086/518005 · Cited by 45
Cheng, D., Gao, H. T., & Li, W. (2018) · Endokrynologia Polska · doi:10.5603/ep.a2018.0036 · Cited by 45
Tfayli, H. M., Ulnach, J. W., Lee, S., Sutton‐Tyrrell, K., & Arslanian, S. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2547 · Cited by 44
Wilding, J. P. H., Gause‐Nilsson, I. A. M., & Persson, A. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.040 · Cited by 44
Double-blind, placebo-controlled trial of pioglitazone for bipolar depression
Aftab, A., Kemp, D. E., Ganocy, S. J., Schinagle, M., Conroy, C. M., Brownrigg, B., D’Arcangelo, N., Goto, T., Woods, N., Serrano, M. B., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.090 · Cited by 44
Naoumova, R. P., Kindler, H. E., Leccisotti, L., Mongillo, M., Khan, M. T., Neuwirth, C. K. Y., Seed, M., Holvoet, P., Betteridge, J. D., & Camici, P. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.070 · Cited by 43
Ibáñez, L., Díaz, M., Sebastiani, G., Sánchez‐Infantes, D., Salvador, C., López‐Bermejo, A., & de Zegher, F. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1671 · Cited by 43
Wang, Y., Wang, Y., Yang, Q., Yan, J., Zhao, C., Cianflone, K., & Wang, D. W. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.09.008 · Cited by 42
Calza, L., Colangeli, V., Manfredi, R., Bon, I., Re, M. C., & Viale, P. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv494 · Cited by 42
Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?
Ko, K. D., Kim, K. K., & Lee, K. R. (2017) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2017.26.2.102 · Cited by 42
Thiazolidinediones as Therapy for Endometriosis: A Case Series
Moravek, M. B., Ward, E. A., & Lebovic, D. I. (2009) · Gynecologic and Obstetric Investigation · doi:10.1159/000230713 · Cited by 41
Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension
Gilbert, K., Nian, H., Yu, C., Luther, J. M., & Brown, N. J. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835e8227 · Cited by 41
Rat Urinary Bladder Carcinogenesis by Dual‐Acting PPARα + γ Agonists
Oleksiewicz, M. B., Southgate, J., Iversen, L., & Egerod, F. L. (2008) · PPAR Research · doi:10.1155/2008/103167 · Cited by 41
Maalouf, N. M., POINDEXTER, J. R., ADAMS-HUET, B. A., Moe, O. W., & Sakhaee, K. (2019) · Kidney International · doi:10.1016/j.kint.2018.11.024 · Cited by 41
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40
Anderson, J. R., Mortimer, K. J., Pang, L., Smith, K., Bailey, H., Hodgson, D. B., Shaw, D. E., Knox, A. J., & Harrison, T. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160257 · Cited by 40
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes
Herz, M., Gaspari, F., Perico, N., Viberti, G. C., Urbanowska, T., Rabbia, M. A., & Kirk, D. A. W. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.037 · Cited by 39
Bonnet, F., Balestre, É., Thiébaut, R., Mercié, P., Dupon, M., Morlat, P., Dabis, F., & (GECSA), F. T. G. D. C. D. S. E. A. (2004) · HIV Medicine · doi:10.1111/j.1468-1293.2004.00200.x · Cited by 38
Rosiglitazone Prevents Free Fatty Acid-Induced Vascular Endothelial Dysfunction
Mittermayer, F., Schaller, G., Pleiner, J., Krzyżanowska, K., Kapiotis, S., Roden, M., & Wolzt, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2130 · Cited by 38
Emerging Therapeutic Role of PPAR–α in Cognition and Emotions
Nisbett, K. E., & Pinna, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00998 · Cited by 37
Fenofibrate Is Effective in Treating Hypertriglyceridemia Associated with HIV Lipodystrophy
Rao, A., D’Amico, S., Balasubramanyam, A., & Maldonado, M. (2004) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200406000-00003 · Cited by 37
Glintborg, D., Højlund, K., Andersen, N. R., Hansen, B. F., Beck‐Nielsen, H., & Wojtaszewski, J. F. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0760 · Cited by 37
Effect of Fenofibrate Medication on Renal Function
Kim, S., Ko, K., Park, S., Lee, D. R., & Lee, J. (2017) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2017.38.4.192 · Cited by 37
Self-citationGarrido‐Urbani, S., Jemelin, S., Deffert, C., Carnésecchi, S., Basset, O., Szyndralewiez, C., Heitz, F., Page, P., Montet, X., Michalik, L., et al. (2011) · PLoS ONE · doi:10.1371/annotation/a392bbef-b0ec-4c70-b403-74a7bad85178 · Cited by 36
Role of the PPAR-α agonist fenofibrate in severe pediatric burn
Elijah, I. E., Børsheim, E., Maybauer, D. M., Finnerty, C. C., Herndon, D. N., & Maybauer, M. O. (2012) · Burns · doi:10.1016/j.burns.2011.12.004 · Cited by 36
Bertrand, O. F., Poirier, P., Rodés‐Cabau, J., Rinfret, S., Title, L. M., Džavík, V., Natarajan, M. K., Angel, J. G. D., Batalla, N., Alméras, N., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.005 · Cited by 34
Quintela, A. M., Jiménez, R., Piqueras, L., Gómez‐Guzmán, M., Haro, J., Zarzuelo-Romero, M. J., Cogolludo, A. L., Sanz, M., Toral, M., Romero, M., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12646 · Cited by 34
Therapeutic Prospects of PPARs in Psychiatric Disorders: A Comprehensive Review
Rolland, B., Deguil, J., Jardri, R., Cottencin, O., Thomas, P., & Bordet, R. (2013) · Current Drug Targets · doi:10.2174/1389450111314070002 · Cited by 34
Bolier, R., de Vries, E. S., Parés, A. R., Helder, J., Kemper, E. M., Zwinderman, K. H., Elferink, R. P. J. O., & Beuers, U. H. (2017) · Trials · doi:10.1186/s13063-017-1966-8 · Cited by 34
Giles, T. D., Elkayam, U., Bhattacharya, M., Pérez, A., & Miller, A. B. (2010) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2010.00154.x · Cited by 33
Bezafibrate for X-Linked Adrenoleukodystrophy
Engelen, M., Tran, L., Ofman, R., Brennecke, J., Moser, A. B., Dijkstra, I. M. E., Wanders, R. J. A., Poll‐The, B. T., & Kemp, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041013 · Cited by 33
Murray, J. A. H., Khanim, F. L., Hayden, R. E., Craddock, C., Holyoake, T. L., Jackson, N., Lumley, M., Bunce, C. M., & Drayson, M. T. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08055.x · Cited by 33
Jones, J. D., Comer, S. D., Metz, V. E., Manubay, J. M., Mogali, S., Ciccocioppo, R., Martinez, S., Mumtaz, M., & Bisaga, A. M. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.10.002 · Cited by 33
Montagner, A., Wahli, W., & Tan, N. S. (2015) · European Journal of Dermatology · doi:10.1684/ejd.2014.2505 · Cited by 31
Self-citationPPAR-α Contributes to the Anti-Inflammatory Activity of 17β-Estradiol
Crisafulli, C., Bruscoli, S., Esposito, E., Mazzon, E., Paola, R. D., Genovese, T., Bramanti, P., Migliorati, G., & Cuzzocrea, S. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.156646 · Cited by 31
Hermans, M. P. (2010) · Current Cardiology Reviews · doi:10.2174/157340310791162686 · Cited by 30
Keith, R. L., Blatchford, P. J., Merrick, D. T., Bunn, P. A., Bagwell, B., Dwyer‐Nield, L. D., Jackson, M. K., Geraci, M. W., & Miller, Y. E. (2019) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-19-0006 · Cited by 30
Juárez-Rojas, J. G., Medina-Urrutia, A. X., Galarza, E. J., Caracas-Portilla, N., Posadas‐Sánchez, R., Cardoso-Saldaña, G. C., Goycochea-Robles, M., Silveira, L., Lino-Pérez, L., Mas‐Oliva, J., et al. (2011) · Lupus · doi:10.1177/0961203311422096 · Cited by 29
Erdmann, E., Califf, R. M., Gerstein, H. C., Malmberg, K., Ruilope, L. M., Schwartz, G. G., Wedel, H., Volz, D., Ditmarsch, M., Svensson, A., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.021 · Cited by 28
Varo, R., Crowley, V. M., Sitoe, A., Madrid, L., Serghides, L., Bila, R., Mucavele, H., Mayor, A. G., Bassat, Q., & Kain, K. C. (2017) · Malaria Journal · doi:10.1186/s12936-017-1858-0 · Cited by 28
Prevention of Cardiovascular Disease Utilizing Fibrates-A Pooled Meta-analysis
Loomba, R., & Arora, R. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181dcf72b · Cited by 27
Thomas, E. L., Potter, E. L., Tosi, I., Fitzpatrick, J. A., Hamilton, G., Amber, V., Hughes, R. I., North, C., Holvoet, P., Seed, M., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.043 · Cited by 27
Fredriksen, J. H., Ueland, T., Dyrøy, E., Halvorsen, B. L., Melby, K. K., Melbye, L., Skålhegg, B. S., Bohov, P., Skorve, J., Berge, R. K., et al. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01410.x · Cited by 26
Can PPARγ agonists have a role in the management of obesity-related hypertension?
Chetty, V. T., & Sharma, A. M. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.11.010 · Cited by 26
Ruilope, L. M., Hanefeld, M., Lincoff, A. M., Viberti, G. C., Reigner, S. M., Mudie, N. Y., Kirk, D. A. W., Malmberg, K., & Herz, M. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-180 · Cited by 26
Levine, T., Bowser, R. P., Hank, N. C., Gately, S. T., Stephan, D. A., Saperstein, D., & Keuren‐Jensen, K. R. V. (2012) · Neurology Research International · doi:10.1155/2012/582075 · Cited by 26
Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis ?
Höftberger, R., Leisser, M., Bauer, J., & Lassmann, H. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0260-9 · Cited by 26
El-Khayat, W. M., Moety, G. A. F. A., Almohamady, M., & Hamed, D. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2015.06.063 · Cited by 25
Brisson, D., Méthot, J., Tremblay, K., Tremblay, M., Perron, P., & Gaudet, D. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328340095e · Cited by 24
Wang, N., Symons, J. D., Zhang, H., Jia, Z., Gonzalez, F. J., & Yang, T. (2008) · Toxicologic Pathology · doi:10.1177/0192623308328545 · Cited by 24
Göke, B., Gause‐Nilsson, I. A. M., & Persson, A. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.041 · Cited by 24
Jones, J. D., Sullivan, M. A., Manubay, J. M., Mogali, S., Metz, V. E., Ciccocioppo, R., & Comer, S. D. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.10.006 · Cited by 24
Pioglitazone as a novel therapeutic approach in chronic granulomatous disease
Migliavacca, M., Assanelli, A. A., Ferrua, F., Cicalese, M. P., Biffi, A., Frittoli, M. C., Silvani, P., Chidini, G., Calderini, E., Mandelli, A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.01.033 · Cited by 24
Dubé, M. P., Komarow, L., Fichtenbaum, C. J., Cadden, J. J., Overton, E. T., Hodis, H. N., Currier, J. S., & Stein, J. H. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ385 · Cited by 23
Ibarra-Lara, L., Sánchez-Aguilar, M., Soria‐Castro, E., Torres-Narváez, J. C., del Valle‐Mondragón, L., Cervantes-Pérez, L. G., Pérez‐Severiano, F., Ramírez-Ortega, M. D. C., Pastelín-Hernández, G. S., Oidor-Chan, V. H., et al. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0356 · Cited by 23
Koopal, C., Marais, A. D., Westerink, J., van der Graaf, Y., & Visseren, F. L. J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m076901 · Cited by 21
Jia, G., & Sowers, J. R. (2018) · Diabetes · doi:10.2337/dbi18-0047 · Cited by 21
Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence
Perkins, K. A., Karelitz, J. L., Michael, V. C., Fromuth, M., Conklin, C. A., Chengappa, K. N. R., Hope, C., & Lerman, C. E. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntv085 · Cited by 20
Hamrén, B., Öhman, K. P., Svensson, M. K. E., & Karlsson, M. O. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011416937 · Cited by 20
Combination Therapy with Metformin and Fenofibrate for Insulin Resistance in Obesity
Xm, L., Li, Y., Zhang, N.-N., Xie, Y.-H., & Shi, Y. Q. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900531 · Cited by 19
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
Munigoti, S. P., & Harinarayan, C. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.131134 · Cited by 19
Zanchi, A., Tappy, L., Lê, K., Bortolotti, M., Theumann, N. H., Halabi, G., Gauthier, T., Mathieu, C., Tremblay, S., Bertrand, P. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109134 · Cited by 19
Han, S. J., Hur, K. Y., Kim, Y. S., Kang, E. S., Kim, S. I., Kim, M. S., Kwak, J. Y., Kim, D. J., Choi, S. H., Cha, B. S., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp567 · Cited by 19
Schroeder, J. R., Phillips, K. A., Epstein, D. H., Jobes, M. L., Furnari, M. A., Kennedy, A., Heilig, M. A., & Preston, K. L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4986-5 · Cited by 19
Lee, H. S., Chang, M., Lee, J., Kim, W., Hwang, I.-C., Kim, D.-H., Park, H., Choi, H., Jo, W., Cha, S.-W., et al. (2014) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2014.04.003 · Cited by 18
Self-citationHong, S. J., Choi, S. C., Cho, J. Y., Joo, H. J., Park, J. H., Yu, C. W., & Lim, D. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-0964 · Cited by 18
Doggrell, S. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.713 · Cited by 18
Moon, K., Lee, J., Lee, H. S., Hwang, I., Dal-Hyun, K., Park, H., Choi, H., Jo, W., Son, W., & Yun, H. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2918 · Cited by 17
Self-citationde Rivas, B., Luque, M., Martell, N., Fernández, C., & Fernández‐Cruz, A. (2007) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.06694.x · Cited by 17
Decochez, K., Rippley, R. K., Miller, J., Smet, M. D., Yan, K. X., Mathijs, Z., Riffel, K. A., Song, H., Zhu, H., Maynor, H. O., et al. (2006) · Drugs in R&D · doi:10.2165/00126839-200607020-00004 · Cited by 17
Rubin, C. J., Ledeine, J.-M., & Fiedorek, F. T. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.028 · Cited by 17
ROS release by PPARβ/δ-null fibroblasts reduces tumor load through epithelial antioxidant response
Tan, E. H. P., Sng, M. K., How, I. S. B., Chan, J. S. K., Chen, J., Tan, C. K., Wahli, W., & Tan, N. S. (2018) · Oncogene · doi:10.1038/s41388-017-0109-8 · Cited by 17
Self-citationChojkier, M., El‐Khayat, H. R., Sabry, D., Donohue, M., & Buck, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031516 · Cited by 16
Rubin, C. J., Viraswami-Appanna, K., & Fiedorek, F. T. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109336048 · Cited by 16
Kawashiri, M., Kobayashi, J., Nohara, A., Noguchi, T., Tada, H., Nakanishi, C., Inazu, A., Mabuchi, H., & Yamagishi, M. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.02.026 · Cited by 16
Suryadevara, S., Ueno, M., Tello‐Montoliu, A., Ferreiro, J. L., Desai, B., Rollini, F., Box, L. C., Zenni, M. M., Guzman, L., Bass, T. A., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-06-0397 · Cited by 15
Madrid-Miller, A., Moreno-Ruíz, L. A., Borrayo–Sánchez, G., Almeida‐Gutiérrez, E., Martínez-Gómez, D. F., & Aguilar, R. J. (2010) · PubMed · Cited by 15
Vogelhuber, M., Feyerabend, S., Stenzl, A., Suedhoff, T., Schulze, M. B., Hübner, J., Oberneder, R., Wieland, W. F., Mueller, S. C., Eichhorn, F., et al. (2014) · Cancer Microenvironment · doi:10.1007/s12307-014-0161-7 · Cited by 15
Kaneda, H., Shiono, T., Miyashita, Y., Takahashi, S., Taketani, Y., Domae, H., Matsumi, J., Mizuno, S., Minami, Y., Sugitatsu, K., et al. (2009) · Heart · doi:10.1136/hrt.2008.162842 · Cited by 15
Gendy, M. N. S., Ciano, P. D., Kowalczyk, W. J., Barrett, S. P., George, T. P., Heishman, S. J., & Foll, B. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201512 · Cited by 15
Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?
Bruckert, É., Duchêne, E., Bonnefont‐Rousselot, D., Hansel, B., Ansquer, J.-C., Dubois, A., & Gaymard, B. M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003693581 · Cited by 14
Henry, R. R., Buse, J. B., Wu, H., Durrwell, L., Mingrino, R., Jaekel, K., Azzouzi, B. E., Andjelković, M., & Herz, M. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12455 · Cited by 14
Gupta, A., Jakubowicz, D. J., & Nestler, J. E. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2016.0009 · Cited by 14
Tungsiripat, M., El‐Bejjani, D., Rizk, N., Dogra, V. S., O’Riordan, M. A., Ross, A. C., Hileman, C. O., Storer, N. J., Harrill, D., & McComsey, G. A. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0187 · Cited by 13
Mulvey, C. K., Ferguson, J. F., Tabita‐Martinez, J., Kong, S. M. Y., Shah, R. Y., Patel, P. N., Master, S. R., Usman, M. H. U., PROPERT, K. J., Shah, R. D., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.002923 · Cited by 13
Liu, A., Kim, S. H., Ariel, D., Abbasi, F., Lamendola, C. A., Cardell, J., Xu, S., Patel, S., Tomasso, V., Mojaddidi, H., et al. (2016) · Sleep Medicine · doi:10.1016/j.sleep.2016.06.005 · Cited by 13
The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients
Richir, M. C., Ellger, B., Teerlink, T., Siroen, M. P. C., Visser, M., Spreeuwenberg, M. D., Girbes, A. R. J., van der Hoven, B., den Berghe, G. V., Wilhelm, A. J., et al. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.06.007 · Cited by 10
Glintborg, D., Hermann, A. P., Rasmussen, L. M., & Andersen, M. (2013) · PubMed · doi:10.3275/8767 · Cited by 9
Straznicky, N. E., Grima, M. T., Sari, C. I., Eikelis, N., Lambert, G. W., Nestel, P. J., Richards, K., Dixon, J. B., Schlaich, M. P., & Lambert, É. (2015) · Metabolism · doi:10.1016/j.metabol.2015.03.006 · Cited by 9
Chen, D. L., Huang, H. J., Byers, D. E., Shifren, A., Belikoff, B. G., Engle, J. T., Arentson, E., Kemp, D., Phillips, S., Scherrer, D. E., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191783 · Cited by 9
A pilot study of MBX-8025 in the treatment of homozygous familial hypercholesterolemia (HoFH)
Gaudet, D., Saheb, S., Bruckert, É., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.068 · Cited by 8
Pfützner, A., Hanefeld, M., Dekordi, L. A., Müller, J., Kleine, I., Fuchs, W. A., & Forst, T. M. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500422 · Cited by 6
Okada, S., Konishi, M., & Ishii, H. (2016) · BMJ Case Reports · doi:10.1136/bcr-2015-213637 · Cited by 5
Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy: A Randomized Trial
van Wijk, J. P. H., de Koning, E. J. P., Cabezas, M. C., op't Roodt, J., Joven, J., Rabelink, T. J., & Hoepelman, A. I. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00009 · Cited by 3
Rosiglitazone and Fenofibrate Additive Effects on Lipids
Slim, A. M., Castillo-Rojas, L. M., Hulten, E., Slim, J. N., Pearce-Moore, D., & Villines, T. C. (2011) · Cholesterol · doi:10.1155/2011/286875 · Cited by 3
Berberoğlu, Z., Yazıcı, A. C., Bayraktar, N., & Demirağ, N. G. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0352-3 · Cited by 3
Koomen, J. V., Heerspink, H. J. L., Schrieks, I. C., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13862 · Cited by 3
Cited by
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
Brase, R. A., Mullin, E. J., & Spink, D. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22030995 · Cited by 374
Jamwal, S., Blackburn, J. K., & Elsworth, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107705 · Cited by 236
Metadata
- Authors
- Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-10-11
- Volume
- 20
- Issue
- 20
- Pages
- 5055
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2980024320
- Cited by
- 264
- References
- 314
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.